|
1.
|
|
15 p, 1.5 MB |
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial O· production in cancer cells
/
Cordani, Marco (Instituto de Investigaciones Biomédicas "Alberto Sols" (CSIC-UAM), IdiPAZ. Biochemistry Department, Universidad Autónoma de Madrid (UAM)) ;
Butera, Giovanna (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Dando, Ilaria (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Torrens-Mas, Margalida (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ;
Butturini, Elena (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Pacchiana, Raffaella (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Oppici, Elisa (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Cavallini, Chiara (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ;
Gasperini, Sara (Section of General Pathology, University of Verona. Department of Medicine) ;
Tamassia, Nicola (Section of General Pathology, University of Verona. Department of Medicine) ;
Nadal-Serrano, Mercedes (VHIO) ;
Coan, Michela (CRO National Cancer Institute Aviano. Division of Molecular Oncology, Department of Translational Research) ;
Rossi, Davide (Institute of Oncology Research) ;
Gaidano, Gianluca (University of Eastern Piedmont. Division of Hematology, Department of Translational Medicine) ;
Caraglia, Michele (Department of Biochemistry, Biophysics and General Pathology, University of Campania "L. Vanvitelli", Naples, Italy) ;
Mariotto, Sofia (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Spizzo, Riccardo (CRO National Cancer Institute Aviano. Division of Molecular Oncology, Department of Translational Research) ;
Roca, Pilar (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ;
Oliver, Jordi (Hospital Universitario Son Espases. Instituto de Investigación Sanitaria de Palma (IdISPa)) ;
Scupoli, Maria Teresa (University of Verona. Research Center LURM (Interdepartmental Laboratory of Medical Research)) ;
Donadelli, Massimo (University of Verona. Department of Neurosciences, Biomedicine and Movement Sciences, Section of Biochemistry) ;
Universitat Autònoma de Barcelona
The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function isoforms actively promote cancer malignancy. A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. [...]
2018 -  10.1038/s41416-018-0288-2
British Journal of Cancer, Vol. 119 (october 2018) , p. 994-1008
|
|
|
2.
|
|
8 p, 788.7 KB |
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)
/
Hájek, R. (University Hospital Ostrava) ;
Masszi, T (St István and St László Hospital of Budapest) ;
Petrucci,M.T. (Sapienza Università di Roma) ;
Palumbo, A. (Università di Torino) ;
Rosiñol, L. (Hospital Clínic de Barcelona) ;
Nagler, Arnon. (Chaim Sheba Medical Center (Israel)) ;
Yong, K.L. (University College London Cancer Institute) ;
Oriol, A. (Institut Germans Trias i Pujol. Institut Català d'Oncologia) ;
Minarik, J. (University Hospital Olomouc and Medical Faculty of Palacky) ;
Pour, L (University Hospital Ostrava) ;
Dimopoulos, M.A. (National and Kapodistrian University of Athens) ;
Maisnar, V. (Charles University Teaching Hospital, Hradec Králové) ;
Rossi, D. (Amedeo Avogadro University of Eastern Piedmont) ;
Kasparu, H. (Hospital Elisabethinen Linz) ;
Van Droogenbroeck, J. (AZ Sint-Jan, Brugge, Belgium) ;
Yehuda, D.B. (Hadassah Medical Center, Jerusalem, Israel) ;
Hardan, I. (Meir Medical Center, Kfar-Saba, Israel) ;
Jenner, M. (Southampton General Hospital, Hampshire, UK) ;
Calbecka, M. (Nicolaus Copernicus Hospital, Toruń Poland) ;
Dávid, M. (University of Pécs, Hungary) ;
de la Rubia, J. (Hospital Universitario La Fe, València) ;
Drach, J. (Medical University of Vienna) ;
Gasztonyi, Z. (Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary) ;
Górnik, S. (Zamojski Szpital Niepubliczny, Zamosc, Poland) ;
Leleu, X. (Hopital Huriez, CHRU, Lille, France) ;
Munder, M. (University Medicine Mainz, Germany) ;
Offidani, M (Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Italy) ;
Zojer, N. (Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria) ;
Rajangam, K. (Onyx Pharmaceuticals, Inc.) ;
Chang, Y.L. (Onyx Pharmaceuticals, Inc.) ;
San-Miguel, J.F. (Clínica Universidad de Navarra-CIMA-IDISNA) ;
Ludwig, H. (Wilhelminen Cancer Research Institute, Vienna, Austria)
This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). [...]
2017 - 10.1038/leu.2016.176
Leukemia, Vol. 31 (2017) , p. 107-114
|
|
|
3.
|
|
11 p, 693.2 KB |
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation
/
Malcikova, J. (Brno, Czech Republic) ;
Tausch, E. (Ulm, Germany) ;
Rossi, D. (Bellinzona, Switzerland) ;
Sutton, L. A. (Stockholm, Sweden) ;
Soussi, T. (Stockholm, Sweden) ;
Zenz, T. (Zürich, Switzerland) ;
Kater, A. P. (Amsterdam, The Netherlands) ;
Niemann, C. U. (Copenhagen, Denmark) ;
González De Castro, David (Belfast, UK) ;
Davi, F. (Paris, France) ;
Gonzalez Diaz, M. (Salamanca, Spain) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gaidano, G. (Novara, Italy) ;
Stamatopoulos, K. (Thessaloniki, Greece) ;
Rosenquist, R. (Stockholm, Sweden) ;
Stilgenbauer, S. (Ulm, Germany) ;
Ghia, P. (Milan, Italy) ;
Pospisilova, S. (Brno, Czech Republic) ;
Universitat Autònoma de Barcelona
In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with resistance to chemoimmunotherapy and a particularly dismal clinical outcome. [...]
2018 - 10.1038/s41375-017-0007-7
Leukemia, Vol. 32 (february 2018) , p. 1070-1080
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
